Nutriband Inc. (FRA:9WV)

Market Cap	45.67M
Revenue (ttm)	1.98M
Net Income (ttm)	-29.99M
Shares Out	n/a
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	999
Average Volume	50
Open	3.480
Previous Close	3.560
Day's Range	3.480 - 3.500
52-Week Range	3.420 - 9.850
Beta	n/a
RSI	43.45
Earnings Date	Apr 28, 2026

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agre...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9WV

Financial Performance

In 2024, Nutriband's revenue was $2.14 million, an increase of 2.60% compared to the previous year's $2.09 million. Losses were -$10.48 million, 91.1% more than in 2023.

Financial numbers in USD